Abstract
Purpose: In the process of developing effective disease modifying drugs for osteoarthritis (OA), biomarkers could prove valuable aids in disease profiling and demonstration of drug efficacy. Though several markers of cartilage extra-cellular matrix (ECM) turnover and inflammation have been proposed, associations with known disease characteristics and prognostic properties are yet to be fully described for all. We aimed to explore a range of serological biomarkers of cartilage ECM turnover; C2M and T2CM, protein fragments (neoepitopes) of matrix metallopeptidase 1- and 13-mediated type II collagen degradation; PRO-C2, a marker of type II collagen formation; and ARGS neoepitope (ARGS), reflecting aggrecan degradation, and their respective associations with pain and baseline characteristics in knee OA patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
